Scott A. Biller

10.3k total citations
53 papers, 2.8k citations indexed

About

Scott A. Biller is a scholar working on Molecular Biology, Organic Chemistry and Cancer Research. According to data from OpenAlex, Scott A. Biller has authored 53 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Molecular Biology, 15 papers in Organic Chemistry and 12 papers in Cancer Research. Recurrent topics in Scott A. Biller's work include Plant biochemistry and biosynthesis (13 papers), Acute Myeloid Leukemia Research (8 papers) and Epigenetics and DNA Methylation (6 papers). Scott A. Biller is often cited by papers focused on Plant biochemistry and biosynthesis (13 papers), Acute Myeloid Leukemia Research (8 papers) and Epigenetics and DNA Methylation (6 papers). Scott A. Biller collaborates with scholars based in United States, Germany and Malaysia. Scott A. Biller's co-authors include John R. Wetterau, Gilbert Stork, Carl P. Ciosek, Thomas Harrity, Robert Mook, Scott D. Rychnovsky, K. Barry Sharpless, John K. Dickson, Eric M. Gordon and Joseph R. Taylor and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Journal of Biological Chemistry.

In The Last Decade

Scott A. Biller

53 papers receiving 2.7k citations

Peers

Countries citing papers authored by Scott A. Biller

Since Specialization

Citations

This map shows the geographic impact of Scott A. Biller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott A. Biller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott A. Biller more than expected).

Fields of papers citing papers by Scott A. Biller

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott A. Biller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott A. Biller. The network helps show where Scott A. Biller may publish in the future.

Co-authorship network of co-authors of Scott A. Biller

This figure shows the co-authorship network connecting the top 25 collaborators of Scott A. Biller. A scholar is included among the top collaborators of Scott A. Biller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott A. Biller. Scott A. Biller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Preclinical Drug Metabolism, Pharmacokinetic, and Pharmacodynamic Profiles of Ivosidenib, an Inhibitor of Mutant Isocitrate Dehydrogenase 1 for Treatment of Isocitrate Dehydrogenase 1-Mutant Malignancies 2021 ·Drug Metabolism and Disposition ·Yue Chen, N. Nagaraja, Bin Fan, Luke Utley, René M. Lemieux, Janeta Popovici-Müller, Lenny Dang, Hyeryun Kim, Liping Yan, Shinsan M. Su, Scott A. Biller, Hua Yang	7
2	Structure and inhibition mechanism of the catalytic domain of human squalene epoxidase 2019 ·Nature Communications ·Anil K. Padyana, Stefan Größ, Lei Jin, Giovanni Cianchetta, Rohini Narayanaswamy, Feng Wang, Rui Wang, Fang Cheng, Xiaobing Lv, Scott A. Biller, Lenny Dang, Christopher E. Mahoney, N. Nagaraja, David Pirman, Zhihua Sui, Janeta Popovici-Müller, Gromoslaw A. Smolen	99
3	MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis 2016 ·Cell Reports ·Katya Marjon, Michael J. Cameron, Phong Quang, Michelle Clasquin, Everton Mandley, Kaiko Kunii, (unknown), Sung Choe, Andrew Kernytsky, Stefan Größ, Zenon Konteatis, Joshua Murtie, Michelle Blake, Jeremy Travins, Marion Dorsch, Scott A. Biller, Kevin M. Marks	280
4	Abstract 3116: AG-221 offers a survival advantage in a primary human IDH2 mutant AML xenograft model 2014 ·Cancer Research ·(unknown), Fang Wang, Jeremy Travins, Yue Chen, Hua Yang, (unknown), Sung Choe, Marion Dorsch, Sam Agresta, David P. Schenkein, Scott A. Biller, Michael Su	6
5	IDH1 Mutant Inhibitor Induces Cellular Differentiation and Offers a Combination Benefit With Ara-C In a Primary Human Idh1 Mutant AML Xenograft Model 2013 ·Blood ·Katharine Yen, René M. Lemieux, Janeta Popovici-Müller, Yue Chen, Hua Yang, (unknown), Sung Choe, Marion Dorsch, Samuel Agresta, David P. Schenkein, Scott A. Biller, Michael Su, Fang Wang	13
6	Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo 2012 ·ACS Medicinal Chemistry Letters ·Janeta Popovici-Müller, Jeffrey O. Saunders, Francesco G. Salituro, Jeremy Travins, Shunqi Yan, Fang Zhao, Stefan Größ, Lenny Dang, Katharine Yen, Hua Yang, Kimberly Straley, Shengfang Jin, Kaiko Kunii, Valeria R. Fantin, Shunan Zhang, (unknown), (unknown), Scott A. Biller, Shinsan M. Su	160
7	High-Content Micronucleus Assay in Genotoxicity Profiling: Initial-Stage Development and Some Applications in the Investigative/Lead-Finding Studies in Drug Discovery 2010 ·Toxicological Sciences ·Milon Mondal, Joseph Gabriels, (unknown), Maria Chiara Magnifico, (unknown), László Urbán, Alan Collis, Dejan Bojanic, Scott A. Biller, Wilfried Frieauff, (unknown), Willi Suter, P. Bentley	8
8	Tetrazole based amides as growth hormone secretagogues 2008 ·Bioorganic & Medicinal Chemistry Letters ·James J. Li, (unknown), Haixia Wang, Jun Li, (unknown), (unknown), Andrés S. Hernández, Scott A. Biller, Jeffrey A. Robl, Joseph A. Tino, (unknown), Ramakrishna Seethala, Paul G. Sleph, Mujing Yan, Gary J. Grover, Neil Flynn, Brian J. Murphy, David Gordon	9
9	Optimization of 1H-tetrazole-1-alkanenitriles as potent orally bioavailable growth hormone secretagogues 2008 ·Bioorganic & Medicinal Chemistry Letters ·Andrés S. Hernández, (unknown), (unknown), Mujing Yan, Ramakrishna Seethala, Paul G. Sleph, Gary J. Grover, Kenneth E.J. Dickinson, (unknown), Timothy W. Harper, W. Griffith Humphreys, Daniel Angelo Longhi, Neil Flynn, Brian J. Murphy, David A. Gordon, Scott A. Biller, Jeffrey A. Robl, Joseph A. Tino	3
10	Discovery, synthesis, and structure–activity studies of tetrazole based growth hormone secretagogues 2007 ·Bioorganic & Medicinal Chemistry Letters ·Andrés S. Hernández, Peter T. W. Cheng, (unknown), (unknown), R.J. George, Gary J. Grover, (unknown), Ramakrishna Seethala, Mark A. Smith, Kenneth E.J. Dickinson, (unknown), Daniel Angelo Longhi, Neil Flynn, Brian J. Murphy, David A. Gordon, Scott A. Biller, Jeffrey A. Robl, Joseph A. Tino	22
11	5-Carboxamido-1,3,2-dioxaphosphorinanes, potent inhibitors of MTP 2004 ·Bioorganic & Medicinal Chemistry Letters ·Richard Sulsky, Jeffrey A. Robl, Scott A. Biller, Thomas Harrity, John R. Wetterau, (unknown), Kern G. Jolibois, Lori Kunselman	26
12	Automated Synthesis and Purification of Amides: Exploitation of Automated Solid Phase Extraction in Organic Synthesis 1997 ·Synthesis ·R. Michael Lawrence, Scott A. Biller, Olga M. Fryszman, Michael A. Poss	51
13	Microsomal Triglyceride Transfer Protein 1995 ·Journal of Biological Chemistry ·Haris Jamil, John K. Dickson, Ching-Hsuen Chu, Michael W. Lago, J. Kent Rinehart, Scott A. Biller, Richard E. Gregg, John R. Wetterau	142
14	Farnesyl Diphosphate-Based Inhibitors of Ras Farnesyl Protein Transferase 1995 ·Journal of Medicinal Chemistry ·Dinesh V. Patel, Robert J. Schmidt, Scott A. Biller, Eric M. Gordon, Simon Robinson, Veeraswamy Manne	57
15	Aromatic isosteres as conformational probes for an isoprenyl subunit: application to inhibitors of squalene synthase 1993 ·Bioorganic & Medicinal Chemistry Letters ·Scott A. Biller, Jeffrey W. Abt, Andrew T. Pudzianowski, (unknown), (unknown), Carl P. Ciosek	19
16	The first potent inhibitor of squalene synthase: a profound contribution of an ether oxygen to inhibitor-enzyme interaction 1991 ·Journal of the American Chemical Society ·Scott A. Biller, Michael J. Sofia, (unknown), Cornelia J. Forster, Eric M. Gordon, Thomas Harrity, (unknown), Carl P. Ciosek	62
17	Isoprenyl phosphinylformates: new inhibitors of squalene synthetase 1991 ·Journal of Medicinal Chemistry ·Scott A. Biller, Carola Y. Förster, Eric M. Gordon, Thomas Harrity, (unknown), (unknown), Carl P. Ciosek	46
18	Phosphorus-containing inhibitors of HMG-CoA reductase. I. 4-[(2-Arylethyl)hydroxyphosphinyl]-3-hydroxybutanoic acids: a new class of cell selective inhibitors of cholesterol biosynthesis 1990 ·Journal of Medicinal Chemistry ·Donald S. Karanewsky, Michael C. Badia, Carl P. Ciosek, Jeffrey A. Robl, Michael J. Sofia, Ligaya M. Simpkins, (unknown), Thomas Harrity, Scott A. Biller, Eric M. Gordon	42
19	Isoprenoid (phosphinylmethyl)phosphonates as inhibitors of squalene synthetase 1988 ·Journal of Medicinal Chemistry ·Scott A. Biller, Cornelia J. Forster, Eric M. Gordon, Thomas Harrity, William Scott, Carl P. Ciosek	69
20	New reaction. Stereospecific vicinal oxyamination of olefins by alkyl imido osmium compounds 1975 ·Journal of the American Chemical Society ·K. Barry Sharpless, (unknown), L. K. TRUESDALE, Scott A. Biller	86

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact